Background--Thromboembolism from nonstenosing carotid plaques may be an underrecognized cause of embolic strokes of undetermined source (ESUS). We evaluated the association between features of nonstenosing atherosclerotic plaque on computed tomographic angiography and ESUS.
I schemic stroke is a major cause of death and disability, and nearly one third of such strokes have no known cause, even after a full diagnostic evaluation. Such cryptogenic strokes pose a significant treatment dilemma, as the prevention of recurrent ischemic stroke relies heavily on identifying cause. Increasingly, such strokes have been classified as embolic strokes of undetermined source (ESUS), with imaging studies confirming the presence of a nonlacunar infarction without hemodynamically significant stenosis in a proximal artery, and no identifiable cardioembolic source. 1 Extracranial internal carotid artery (ICA) atherosclerotic disease is a known risk factor for acute stroke, with established guidelines focused on the management of ≥50% stenosis. 2, 3 However, recent studies have suggested that certain vulnerable plaques with features that can be readily identified on standard imaging may present a risk factor for acute embolic infarction despite not causing any hemodynamically significant stenosis. As such, there has been recent interest in high-risk nonstenosing plaques as a potential culprit for a substantial proportion of strokes classified as ESUS. [4] [5] [6] [7] [8] [9] [10] [11] While several high-risk plaque features have been examined by computed tomographic angiography (CTA) in patients with stenotic lesions, it is uncertain which features are most strongly associated with stroke in patients with nonstenotic plaques. [12] [13] [14] [15] [16] Furthermore, there are few data comparing plaque features between stroke subtypes, particularly the ESUS subgroup in comparison to other embolic stroke causes, such as strokes secondary to cardioembolism.
We evaluated multiple plaque features on CTA in patients with acute ischemic stroke and no hemodynamically significant stenosis. We performed a within-subject analysis in which we compared plaque features of the ipsilateral versus contralateral side of ischemic stroke. We hypothesized that certain plaque features are more likely to be associated with ipsilateral strokes in patients with ESUS, whereas these features would not be associated with infarct side for cardioembolic cases.
Methods

Study Design
We performed a within-subject analysis comparing the prevalence of high-risk nonstenosing plaque on the side ipsilateral to acute infarction versus the contralateral side (control side) among ESUS patients enrolled in CAESAR (Cornell Acute Stroke Academic Registry). We also performed the same analysis on patients with strokes of cardioembolic cause, who were included as a negative control group because they were not expected to have side-to-side differences in high-risk plaque prevalence. Strokes secondary to small-vessel occlusion or other causes were excluded because of small sample sizes and heterogeneity in this group.
The institutional review board at Weill Cornell Medicine approved this study and waived the informed consent requirement. Deidentified data that support the findings of this study are available from the corresponding author upon reasonable request.
Patient Population
All patients hospitalized at New York-Presbyterian Hospital/ Weill Cornell Medical Center for acute ischemic stroke are prospectively enrolled in the American Heart Association's Get With The Guidelines-Stroke registry. Trained hospital analysts prospectively collect data on demographics, vascular risk factors and comorbidities, stroke severity, and in-hospital treatments and outcomes. CAESAR combines the Get With The Guidelines data plus additional retrospectively collected clinical, laboratory, and radiographic data. Patients' medical records from the stroke hospitalization are reviewed by a panel of at least 3 neurologists who adjudicate the cause of stroke per the TOAST (Trial of ORG 10172 in Acute Stroke Treatment) classification 17 and per the recently proposed definitions for ESUS. 11 For this analysis, we included consecutive cardioembolic and ESUS patients who were admitted to the hospital between 2011 and 2015, had a magnetic resonance imaging study of the brain demonstrating a unilateral acute infarction in the anterior circulation, and had a CTA with <50% ICA stenosis bilaterally. Patients with apparent severe aortic arch atherosclerosis or common carotid artery stenosis were excluded. 
Clinical Perspective
What Is New?
• This is the first study evaluating multiple carotid plaque features in embolic strokes of undetermined source patients using cardioembolic stroke cases as a control. • Among multiple internal carotid artery plaque features analyzed, we found that embolic strokes of undetermined source patients had greater total plaque thickness on the side ipsilateral to their brain infarct as compared with the contralateral, infarct-free side. • This relationship did not hold for patients with a known cardioembolic source of infarction.
What Are the Clinical Implications?
• Our findings suggest that increased plaque thickness is a mechanism for stroke in a subgroup of embolic strokes of undetermined source patients. • By further defining this subgroup, we may be able to identify patients who could potentially benefit from trials of aggressive therapy aimed at plaque reduction.
Measurements
ICA plaque features at the carotid bifurcation were retrospectively characterized on helical axial CTA images (0.625 mm) and measured by a single radiologist according to definitions based on previous studies (Table 1) . 10, 16, [18] [19] [20] The reader was blinded to the clinical information and brain magnetic resonance imaging study findings. The degree of stenosis was measured on both ICAs according to the NASCET (North American Symptomatic Carotid Endarterectomy Trial) criteria. 21, 22 The vessel was then evaluated 2 cm proximal and distal to the bifurcation, and the axial slice with the largest total plaque thickness was measured perpendicular to the long axis of the vessel. 10 Soft plaque thickness and calcified plaque thickness were measured in the same fashion. Distal common carotid artery wall thickness was defined as the maximal thickness of the distal common carotid artery where no plaque was present. 18 Ulceration was defined as focally defined contrast extending beyond the vascular lumen by ≥1.5 mm. 16, 19 Lastly, we measured the perivascular fat attenuation similar to prior studies, although, given our focus on nonstenosing plaque, measurements were made at the level of greatest plaque thickness rather than maximal stenosis (Figure) . 20 We have previously demonstrated reproducibility of perivascular fat attenuation and plaque thickness measurements, with excellent interrater reliability. 13, 20 The magnetic resonance imaging studies were reviewed independently, and the reader was blinded to carotid CTA imaging. The presence of acute infarction was determined based on diffusion-weighted imaging.
Statistical Analysis
We compared the mean total plaque thickness on the side ipsilateral and contralateral to the acute infarct using a 2tailed paired t test. We performed the same analysis on the secondary variables of soft plaque thickness, calcified plaque thickness, distal common carotid artery wall thickness, and perivascular fat attenuation. We assessed side-to-side differences in the prevalence of plaque ulceration using McNemar's test for paired observations. We performed the above analyses separately in ESUS cases and cardioembolic cases. In sensitivity analyses, we evaluated only ESUS cases with cortical infarcts, and we excluded ESUS patients who developed atrial fibrillation after discharge.
Results
Patient Characteristics
From 138 patients with available CTA and magnetic resonance imaging study data, 91 fit the inclusion criteria, of whom 36 had ESUS and 55 had cardioembolic stroke ( Table 2 ). The mean age of ESUS patients was 65AE17 years, with a mean National Institutes of Health stroke scale upon arrival to the emergency room of 9.0AE7.0. The mean age of cardioembolic patients was 70.0AE12.7 years, with mean National Institutes of Health stroke scale of 11.5AE7.8. Cardioembolic patients were significantly more likely to have heart failure and thrombolysis administered, and ESUS patients were more likely to undergo transesophageal echocardiogram.
Plaque Features in ESUS Patients
Among ESUS patients, mean stenosis, as measured by the NASCET criteria, was 4.3AE11% ipsilateral to the side of infarction, and 1.4AE8.2% on the contralateral side. Among all ESUS patients, total plaque thickness was significantly higher on the side ipsilateral to the infarction (2.1AE2.0 mm) compared with the contralateral, infarct-free side (1.2AE1.5 mm) (P=0.006) ( Table 3 ). These results were the same in a subsequent sensitivity analysis limited to only ESUS cases with cortical infarcts and excluding ESUS cases with postdischarge atrial fibrillation. In analyses of secondary variables, calcified plaque thickness, perivascular fat attenuation, distal common carotid artery wall thickness, and the prevalence of ulceration were not significantly different between the ipsilateral and contralateral sides. Soft plaque was nonsignificantly thicker on the ipsilateral side (1.7AE2.1 mm) than on the contralateral side (1.1AE1.4 mm) (P=0.07).
Plaque Features in Cardioembolic Stroke Patients
Among patients with cardioembolic stroke, total plaque thickness was similar on the side ipsilateral to infarction (1.9AE1.6 mm) compared with the contralateral, infarct-free side (1.8AE1.6 mm) (P=0.32). There were also no side-to-side differences in any of the secondary plaque features we assessed. Mean stenosis ipsilateral to the infarction side was 1.8AE7.6%, and 3.9AE11% contralateral to the infarction side.
Discussion
In a prospective, single-center registry, we studied the association between features of nonstenosing carotid plaque on CTA and ipsilateral ischemic stroke. We found that ESUS patients had greater carotid plaque thickness on the side ipsilateral to their brain infarct as compared with their contralateral, infarct-free side. No such association was found in cardioembolic stroke patients, who we assessed as a negative control group because they already had an explanation for their infarct. These findings suggest that nonstenosing plaque identifiable on CTA may be the mechanism underlying a subset of ESUS cases. We and others have previously reported associations between nonstenosing plaque on CTA or magnetic resonance angiography and ipsilateral infarction in patients with ESUS. 4, [8] [9] [10] Prior studies using CTA have assessed only a single plaque feature and have not included a negative control group with a defined cause of stroke, such as cardioembolic stroke patients. 10 We have previously found an association between intraplaque hemorrhage on magnetic resonance angiography and ipsilateral infarction in ESUS patients, and no such association in cardioembolic strokes. 8 However, magnetic resonance angiography may not be universally available, and CTA has advantages in the evaluation of acute ischemic stroke. In this context, our study adds novel information that indicates that nonstenosing plaque may be one mechanism underlying ESUS, and that such plaques can be readily detectable on routine CTA studies. Among the individual components of nonstenosing plaque, we found a nonsignificant association in ESUS patients between soft plaque and ipsilateral infarction, and no association at all between calcified plaque and ipsilateral infarction. This is consistent with previous studies of patients with >50% stenosis. 14, 23, 24 We did not find any association with other plaque features, such as ulceration. Since only a subgroup of ESUS patients had plaque ulceration, our sample size may have limited our ability to detect differences in the prevalence of ulceration ipsilateral versus contralateral to the side of infarction in ESUS patients. In the future, larger studies are warranted, which may reveal associations with additional plaque features.
Our findings may have implications for therapeutic strategies to prevent recurrent stroke. The standard set of preventive therapies currently recommended after ESUS includes antiplatelet therapy, statin therapy, and blood pressure control. Recent attempts to improve outcomes by using anticoagulant therapy in the overall ESUS population were unsuccessful. 25, 26 Such results suggest the need for more tailored therapy according to the likely mechanism of ESUS. Our findings suggest that for a subset of patients, specific measures directed at stabilizing atherosclerotic plaque, such as intensive low-density lipoprotein lowering and potentially mild immunosuppressive medications, 27 may ultimately be helpful. Such strategies will need to be tested in randomized clinical trials.
There are limitations to this study. First, our sample of ESUS cases is from a single institution, our work was performed without prespecified power analyses, and we lacked the sample size needed to perform meaningful receiver operating characteristics analysis. Future larger studies will be needed to determine the degree of side-to-side asymmetry in plaque thickness that might best identify ESUS cases that are caused by artery-to-artery embolism. Second, our study looked at the association between plaque features on CTA after a stroke, rather than before. We believe that this is a clinically relevant approach for improving secondary stroke prevention efforts. However, to broaden the relevance of these findings to stroke-free individuals, it will be important for future studies to assess the relationship between plaque thickness and risk of first-time stroke.
Despite these limitations, our study suggests that quantitative analysis of routine CTA studies may allow elucidation of underlying embolic sources in ESUS cases. Future investigations are required to determine optimal thresholds of plaque thickness on CTA for identifying a subgroup of ESUS patients who could be enrolled in trials of aggressive therapy directed at plaque reduction, including high-intensity lipid lowering and ultrapotent antiplatelet therapy.
Sources of Funding
Dr Kamel is supported by the NIH (R01NS097443 and R01HL144541) and the Michael Goldberg Research Fund. Dr Gupta is supported by the NIH (R01HL144541 and R21HL145427).
Disclosures
Dr Kamel serves on an end point adjudication committee for a clinical trial of a diabetes mellitus medication made by Boehringer-Ingelheim. The remaining authors have no disclosures to report.
